Literature DB >> 8512018

Expression and release of interleukin-1 by human glioblastoma cells in vitro and in vivo.

T Gauthier1, M F Hamou, L Monod, P Gallay, S Carrel, N de Tribolet.   

Abstract

The present study demonstrates interleukin-1 (IL-1) production by human glioblastoma cells both in vitro and in vivo. The presence of IL-1 alpha and IL-1 beta transcripts was analyzed in 4 cell lines. IL-1 alpha mRNA was expressed constitutively in one cell line whereas constitutive IL-1 beta mRNA could not be detected in any of the cell lines. IL-1 alpha transcripts could be induced with phorbol myristate acetate (PMA) or PMA plus lipopolysaccharide (LPS) in 2 of 4 cell lines and IL-1 beta mRNA in 2 of 4 cell lines. Culture fluid from these cell lines was tested for the presence of IL-1 using a specific radio-immuno-assay for either IL-1 alpha or IL-1 beta. In agreement with the results on RNA, one of 4 cell lines was found to constitutively produce IL-1 alpha but not IL-1 beta. After treatment with PMA and LPS, IL-1 alpha was detected in the culture fluid from two other lines and IL-1 beta in the medium from three lines. That the IL-1 produced by these cell lines was biologically active was confirmed in a two step thymocyte proliferation assay. IL-1 like activity was detected in all samples that were positive in the radio-immuno-assay. Finally, immunohistological analysis on fresh frozen tumour sections provided evidence for IL-1 production by glioblastoma cells in vivo. Fourteen out of 28 glioblastomas were stained with an anti-IL-1 alpha monoclonal antibody while none of them was stained with an anti-IL-1 beta antibody.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8512018     DOI: 10.1007/BF01809276

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  28 in total

1.  Positive signal transduction via surface CD4 molecules does not need coexpression of the CD3/TcR complex.

Authors:  S Carrel; S Salvi; P Gallay; C Rapin; R P Sekaly
Journal:  Res Immunol       Date:  1991-02

2.  Intracerebroventricular infusion of interleukin 1 rapidly decreases peripheral cellular immune responses.

Authors:  S K Sundar; K J Becker; M A Cierpial; M D Carpenter; L A Rankin; S L Fleener; J C Ritchie; P E Simson; J M Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

3.  Constitutive and PMA-induced interleukin-1 production by the human astrocytoma cell line T24.

Authors:  J C Lee; P L Simon; P R Young
Journal:  Cell Immunol       Date:  1989-02       Impact factor: 4.868

4.  Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas.

Authors:  M C Kuppner; M F Hamou; N de Tribolet
Journal:  J Neuroimmunol       Date:  1990 Sep-Oct       Impact factor: 3.478

5.  Production of hemopoietic colony-stimulating factors by astrocytes.

Authors:  U V Malipiero; K Frei; A Fontana
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

6.  Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.

Authors:  L Monod; A C Diserens; C V Jongeneel; S Carrel; P Ronco; P Verroust; N de Tribolet
Journal:  Int J Cancer       Date:  1989-11-15       Impact factor: 7.396

7.  Response of glioma cells to interferon-gamma: increase in class II RNA, protein and mixed lymphocyte reaction-stimulating ability.

Authors:  M Takiguchi; J P Ting; S C Buessow; C Boyer; Y Gillespie; J A Frelinger
Journal:  Eur J Immunol       Date:  1985-08       Impact factor: 5.532

8.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) production by glioblastoma cells. Despite the presence of inducing signals GM-CSF is not expressed in vivo.

Authors:  K Frei; D Piani; U V Malipiero; E Van Meir; N de Tribolet; A Fontana
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

9.  Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells.

Authors:  H Baumann; V Onorato; J Gauldie; G P Jahreis
Journal:  J Biol Chem       Date:  1987-07-15       Impact factor: 5.157

10.  Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Authors:  W H Brooks; M G Netsky; D E Normansell; D A Horwitz
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  8 in total

1.  Granulocyte colony-stimulating factor (G-CSF) production by astrocytoma cells and its effect on tumor growth.

Authors:  T Kikuchi; S Nakahara; T Abe
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

Review 2.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

Review 3.  Molecular alterations in glioblastoma: potential targets for immunotherapy.

Authors:  Azizul Haque; Naren L Banik; Swapan K Ray
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

4.  At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop.

Authors:  Stefan Kaluz; Erwin G Van Meir
Journal:  J Mol Med (Berl)       Date:  2011-02       Impact factor: 4.599

5.  In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines.

Authors:  Hani J Marcus; Keri L H Carpenter; Stephen J Price; Peter J Hutchinson
Journal:  J Neurooncol       Date:  2009-08-28       Impact factor: 4.130

6.  Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells.

Authors:  Lei Wang; Ziyan Liu; Sivasai Balivada; Tej Shrestha; Stefan Bossmann; Marla Pyle; Loretta Pappan; Jishu Shi; Deryl Troyer
Journal:  Stem Cell Res Ther       Date:  2012-02-10       Impact factor: 6.832

Review 7.  Modulation of the Complement System by Neoplastic Disease of the Central Nervous System.

Authors:  Steven K Yarmoska; Ali M Alawieh; Stephen Tomlinson; Kimberly B Hoang
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

8.  Anti-C1-inactivator treatment of glioblastoma.

Authors:  Karolina Förnvik; Jonatan Ahlstedt; Kurt Osther; Leif G Salford; Henrietta Nittby Redebrandt
Journal:  Oncotarget       Date:  2018-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.